Apri Calculator - Liver Fibrosis Risk by AST

An apri calculator estimates liver fibrosis risk from a routine blood test by combining AST, the lab upper limit of normal, and the platelet count into the AST to Platelet Ratio Index. The score and a classification label map to the WHO 2015 cut-offs, so APRI can screen for significant fibrosis or cirrhosis in hepatitis B and C settings without an immediate liver biopsy.

• • Hepatitis C follow-up: screen adults with chronic hepatitis C for significant fibrosis or cirrhosis between specialist visits.
• • Hepatitis B monitoring: follow adults with chronic hepatitis B who already have routine AST and platelet panels.
• • Pre-treatment baseline: build a numeric fibrosis baseline before starting antiviral therapy.
• • Resource-limited screening: support population-level screening in clinics without elastography or access to a hepatologist.

APRI is a screening score, not a diagnosis. A high score raises the index of suspicion for significant fibrosis or cirrhosis, but the WHO and AASLD guidelines still recommend elastography or liver biopsy when the result will change management.

The inputs are already on standard liver function and complete blood count panels, which is why APRI is widely used in hepatitis cohorts where lab data is available but imaging is not.

For a parallel blood-test-derived score that estimates cardiovascular risk from the standard lipid panel, the LDL Calculator takes Total Cholesterol, HDL, and triglycerides and returns a Friedewald LDL value, which keeps this tool sitting next to a familiar liver-and-heart panel pair.

The apri calculator uses the WHO 2015 version of the AST to Platelet Ratio Index, the same formula published by Wai and colleagues in Hepatology in 2003. The score is the patient AST divided by the AST upper limit of normal, divided again by the platelet count, then multiplied by 100.

• AST: patient AST in U/L from the most recent liver function panel.
• AST_upper_limit_of_normal: upper limit of normal printed on the lab report, typically 35 or 40 U/L for adults.
• Platelets: platelet count in 10^9/L, the same unit used in the original APRI formula.

The same arithmetic works for any lab, but the AST upper limit of normal must be entered carefully. Common adult values are 35 and 40 U/L, and labs that use 35 U/L will produce a slightly higher APRI for the same patient than labs that use 40 U/L.

The calculator rounds the result to two decimal places so the score matches the precision used in published APRI research.

According to WHO hepatitis C fact sheet, fibrosis assessment in chronic hepatitis C can be done through non-invasive blood tests such as the AST to Platelet Ratio Index rather than liver biopsy, which is no longer the routine reference standard.

When a clinician wants a second non-invasive screen for organ function on the same visit, the GFR Calculator turns serum creatinine, age, gender, and race into an eGFR using the CKD-EPI equation, which makes this tool pair naturally with a kidney function score.

Four concepts drive the score. Naming them keeps the index from being read as a black box.

The platelet signal comes from the spleen. As liver fibrosis advances, portal pressure rises, the spleen sequesters more platelets, and the circulating platelet count falls. APRI captures that signal by dividing by the platelet count.

A small adjustment to the AST upper limit of normal changes every APRI for every patient, which is one reason the calculator keeps the ULN field editable.

Because APRI is a ratio built from a numerator over a denominator, the Cholesterol Ratio Calculator is a useful reference for how a single ratio is read against a published cut-off in routine clinical practice.

The form runs on three numbers that are already part of standard liver and hematology panels.

1. 1 Enter AST in U/L: type the AST value from the most recent liver function panel. Most adult values sit between 10 and 100 U/L even when the liver is healthy.
2. 2 Enter the AST upper limit of normal: match the upper limit of normal printed on the same lab report. Common adult values are 35 and 40 U/L; the calculator defaults to 40 U/L.
3. 3 Enter the platelet count in 10^9/L: type the platelet count from the most recent complete blood count in 10^9/L. The same value in 1000 per microL is interchangeable, so 200 x 10^9/L equals 200,000 per microL.
4. 4 Read the score and classification: check the rounded APRI score and the fibrosis interpretation label. The label follows the WHO 2015 bands, so a score under 0.5 is low fibrosis, 0.5 to 1.5 is indeterminate, above 1.5 is significant fibrosis, and 2.0 or higher is cirrhosis-suggestive.
5. 5 Pair the result with clinical context: review the score alongside the patient history, viral load, imaging, and other liver markers before changing any treatment plan.

A 55-year-old patient with chronic hepatitis B has a recent liver panel with AST 60 U/L on a lab that uses 40 U/L as the upper limit of normal, and a platelet count of 90 x 10^9/L. The calculator returns an APRI of 1.67, which lands in the WHO 2015 significant-fibrosis band. The next step is elastography or specialist referral.

When a workflow needs a second point-based clinical score alongside APRI, the TI-RADS Calculator totals ultrasound feature points against ACR biopsy and follow-up size thresholds, which keeps this tool next to another structured interpretation workflow.

Using this calculator alongside routine liver panels has concrete advantages for clinicians and patients.

• • Built on routine lab work: the only inputs are AST, the AST upper limit of normal, and the platelet count, which are already on most standard liver function and complete blood count panels.
• • WHO 2015 cut-offs built in: the four WHO 2015 bands at 0.5, 1.5, and 2.0 are applied automatically, so the classification stays consistent with the published screening thresholds.
• • Editable AST upper limit: the AST upper limit of normal is editable, so the same form works for labs that report 35, 40, or another adult reference value without changing the underlying formula.
• • Quick to recalculate: every change to AST, AST upper limit, or platelets updates the score instantly, which makes it practical to re-run the calculation after each new lab draw.
• • Useful in resource-limited clinics: APRI is one of the WHO-recommended low-cost screening tools for settings where elastography or liver biopsy is not readily available, so the score can support earlier triage.
• • Easy to document: the rounded score and the classification label fit on a single clinic note.

The score is a planning tool, not a treatment recommendation. The WHO 2015 guidelines are explicit that APRI is for screening and triage, and that elastography or liver biopsy remains the next step when the score will change care.

Four factors move the score the most.

• • APRI is a screening tool, not a stand-alone diagnosis. A score in the indeterminate or significant-fibrosis band still needs elastography or liver biopsy confirmation before any treatment change.
• • The score is least accurate in the indeterminate band. WHO 2015 data show the score has lower sensitivity in patients with mild fibrosis, and other non-invasive tests such as FibroScan or FIB-4 may be added when the patient falls between 0.5 and 1.5.
• • Acute hepatitis, alcohol use, and certain medications can raise AST without raising the true fibrosis stage. A transiently high APRI during acute illness should be re-checked after recovery before being read as a fibrosis signal.

The score is calibrated for adults. Pediatric reference ranges for AST and platelets differ, so the calculator is best used for adult screening.

According to Wai et al. (Hepatology 2003), the AST to Platelet Ratio Index is calculated as the patient AST divided by the AST upper limit of normal, divided by the platelet count in 10^9 per L, then multiplied by 100.

According to University of Washington Hepatitis C Online, an APRI score of at least 2.0 is more specific for cirrhosis while a score of at least 1.0 is used to detect severe fibrosis or cirrhosis, with APRI best used in combination with other non-invasive markers rather than as a sole staging method.

When the patient needs a clinical formula that turns routine body measurements into a dosing or staging input, the Body Surface Area Calculator offers Mosteller, DuBois, and Haycock, which keeps this tool next to a familiar body-measurement formula.